{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:04:28Z","timestamp":1789923868055,"version":"4.0.1"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD","award":["LBPMC"],"award-info":[{"award-number":["LBPMC"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.pharmthera.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T03:33:11Z","timestamp":1479353591000},"page":"181-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Intensive LDL-cholesterol lowering therapy and neurocognitive function"],"prefix":"10.1016","volume":"170","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VirginiaJ.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DimitriP.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.11.001_bb0005","doi-asserted-by":"crossref","first-page":"9673","DOI":"10.1007\/s11357-014-9673-9","article-title":"Associations between APOE and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: The HALCyon programme","volume":"36","author":"Alfred","year":"2014","journal-title":"Age (Dordrecht, Netherlands)"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjca.2016.04.013","article-title":"Monoclonal antibodies for the treatment of hypercholesterolemia: Targeting PCSK9","author":"Alkindi","year":"2016","journal-title":"The Canadian Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0015","series-title":"Amgen announces positive top-line results from phase 3 GAUSS-3 trial of Repatha (evolocumab) in statin-intolerant patients with high cholesterol [press release]","author":"Amgen","year":"2016"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0020","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.euroneuro.2014.02.003","article-title":"Gender-specific associations between lipids and cognitive decline in the elderly","volume":"24","author":"Ancelin","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/01.wnl.0000288181.00826.63","article-title":"Statins, incident Alzheimer disease, change in cognitive function, and neuropathology","volume":"70","author":"Arvanitakis","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/0003319708321102","article-title":"Effects of atorvastatin on vascular intimal hyperplasia: An experimental rodent model","volume":"60","author":"Aydin","year":"2009","journal-title":"Angiology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/jcsm.12109","article-title":"Discussion around statin discontinuation in older adults and patients with wasting diseases","volume":"7","author":"Banach","year":"2016","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12944-015-0169-0","article-title":"Lipids, blood pressure and kidney update 2015","volume":"14","author":"Banach","year":"2015","journal-title":"Lipids in Health and Disease"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0045","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.2174\/13816128113199990303","article-title":"PCSK9 inhibition - A novel mechanism to treat lipid disorders?","volume":"19","author":"Banach","year":"2013","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0050","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Archives of Medical Science"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bcp.2013.10.030","article-title":"Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets","volume":"88","author":"Barone","year":"2014","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0070","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1523\/JNEUROSCI.5633-07.2008","article-title":"Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits","volume":"28","author":"Belinson","year":"2008","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2015.02.016","article-title":"Hypercholesterolemia in elders is associated with slower cognitive decline: A prospective, population-based study (NEDICES)","volume":"350","author":"Benito-Leon","year":"2015","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1749-6632.2002.tb04839.x","article-title":"Cholesterol in Alzheimer's disease and tauopathy","volume":"977","author":"Burns","year":"2002","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.phrs.2011.04.007","article-title":"Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders","volume":"64","author":"Butterfield","year":"2011","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.taap.2016.06.032","article-title":"Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin","volume":"306","author":"Camerino","year":"2016","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0095","author":"ClinicalTrials.gov NCT01764633"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0100","author":"ClinicalTrials.gov NCT02207634"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0105","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-510X(01)00529-9","article-title":"Use of statins in CNS disorders","volume":"187","author":"Cucchiara","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0115","first-page":"885","article-title":"Grapefruit juice\u2013drug interactions: Importance for pharmacotherapy","volume":"114","author":"Cuciureanu","year":"2010","journal-title":"Revista Medico-Chirurgicala A Societatii de Medici si Naturalisti din Iasi"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00041433-200104000-00003","article-title":"Cholesterol metabolism in the brain","volume":"12","author":"Dietschy","year":"2001","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1074248414539562","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibitors: An emerging lipid-lowering therapy?","volume":"20","author":"Dragan","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nbd.2009.05.005","article-title":"Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients","volume":"35","author":"Eckert","year":"2009","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","article-title":"Statin-associated adverse cognitive effects: Survey results from 171 patients","volume":"29","author":"Evans","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0140","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMp1508120","article-title":"Reducing LDL with PCSK9 inhibitors\u2014The clinical benefit of lipid drugs","volume":"373","author":"Everett","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0145","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0150","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneurol.2012.85","article-title":"Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures","volume":"69","author":"Galasko","year":"2012","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0155","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1523\/JNEUROSCI.4144-09.2009","article-title":"Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease","volume":"29","author":"Ghosh","year":"2009","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.11622\/smedj.2013044","article-title":"Cytochrome P450 drug interactions with statin therapy","volume":"54","author":"Goh","year":"2013","journal-title":"Singapore Medical Journal"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0170","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.66.3.343","article-title":"Contribution of vascular risk factors to the progression in Alzheimer disease","volume":"66","author":"Helzner","year":"2009","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0175","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/jnnp.74.11.1530","article-title":"Serum lipids and memory in a population based cohort of middle age women","volume":"74","author":"Henderson","year":"2003","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-016-0550-5","article-title":"Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro\/con debate","volume":"14","author":"Hobbs","year":"2016","journal-title":"BMC Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0185","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3233\/JAD-2010-091381","article-title":"Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls","volume":"21","author":"Hyttinen","year":"2010","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrm2336","article-title":"Cellular cholesterol trafficking and compartmentalization","volume":"9","author":"Ikonen","year":"2008","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0195","article-title":"PCSK9 inhibition with monoclonal antibodies\u2014Modern management of hypercholesterolemia","author":"Ito","year":"2016","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jalz.2008.02.001","article-title":"The atorvastatin\/donepezil in Alzheimer's disease study (LEADe): Design and baseline characteristics","volume":"4","author":"Jones","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3233\/JAD-121138","article-title":"Very old adults with better memory function have higher low-density lipoprotein cholesterol levels and lower triglyceride to high-density lipoprotein cholesterol ratios: KOCOA project","volume":"34","author":"Katsumata","year":"2013","journal-title":"Journal of Alzheimer's Disease"},{"issue":"906-915","key":"10.1016\/j.pharmthera.2016.11.001_bb0210","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0215","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1113\/jphysiol.2014.288209","article-title":"Cholesterol modulates open probability and desensitization of NMDA receptors","volume":"593","author":"Korinek","year":"2015","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0220","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"American Journal of Human Genetics"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.schres.2011.04.005","article-title":"Cholesterol and cognition in schizophrenia: A double-blind study of patients randomized to clozapine, olanzapine and haloperidol","volume":"130","author":"Krakowski","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0230","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11011-016-9797-y","article-title":"Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory","volume":"31","author":"Leritz","year":"2016","journal-title":"Metabolic Brain Disease"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0235","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pnpbp.2015.11.013","article-title":"Statins and the brain: New perspective for old drugs","volume":"66","author":"Ling","year":"2016","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0240","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3349\/ymj.2015.56.1.89","article-title":"Insulin resistance is an important risk factor for cognitive impairment in elderly patients with primary hypertension","volume":"56","author":"Ma","year":"2015","journal-title":"Yonsei Medical Journal"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003160.pub3","article-title":"Statins for the prevention of dementia","author":"McGuinness","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/jnr.10585","article-title":"Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer's disease?","volume":"72","author":"Michikawa","year":"2003","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.JAA.0000475471.02134.37","article-title":"Are statins protective or harmful to cognitive function?","volume":"29","author":"Mospan","year":"2016","journal-title":"JAAPA"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0265","article-title":"Statin-associated myopathy and the quest for biomarkers: Can we effectively predict statin-associated muscle symptoms?","author":"Muntean","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0270","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0275","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1741-7015-10-154","article-title":"The impact of statins on psychological wellbeing: A systematic review and meta-analysis","volume":"10","author":"O'Neil","year":"2012","journal-title":"BMC Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuron.2012.01.034","article-title":"Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome","volume":"77","author":"Osterweil","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0285","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0290","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jad.2013.11.026","article-title":"Statins use and risk of depression: A systematic review and meta-analysis","volume":"160","author":"Parsaik","year":"2014","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0295","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2016.07.239","article-title":"Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis","volume":"222","author":"Peng","year":"2016","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001713","article-title":"Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: A Mendelian randomization analysis","volume":"11","author":"Proitsi","year":"2014","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0305","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neulet.2006.08.048","article-title":"Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease","volume":"408","author":"Raygani","year":"2006","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0310","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/archneur.62.7.1047","article-title":"Statin use and the risk of incident dementia: The cardiovascular health study","volume":"62","author":"Rea","year":"2005","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0315","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","article-title":"Associations between serum cholesterol levels and cerebral amyloidosis","volume":"71","author":"Reed","year":"2014","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0320","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"64","author":"Reiner","year":"2011","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0325","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archneur.61.5.705","article-title":"Relation of plasma lipids to Alzheimer disease and vascular dementia","volume":"61","author":"Reitz","year":"2004","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0330","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: A systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0335","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archneur.59.2.223","article-title":"Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people","volume":"59","author":"Rockwood","year":"2002","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0345","series-title":"American College of Cardiology 2015 scientific sessions; march 15, 2015; San Diego, CA. Abstract 402-08","article-title":"Effect of the PCSK9 inhibitor evolocumab on cardiovascular outcomes","author":"Sabatine","year":"2015"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0350","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0355","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","article-title":"Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials","volume":"241","author":"Sahebkar","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0360","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fnagi.2015.00199","article-title":"The roles of lipid and glucose metabolism in modulation of beta-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease","volume":"7","author":"Sato","year":"2015","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0365","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-3940(02)00164-7","article-title":"Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls","volume":"324","author":"Schonknecht","year":"2002","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0370","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jps.2600800905","article-title":"Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin","volume":"80","author":"Serajuddin","year":"1991","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0375","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/14656566.2016.1118055","article-title":"Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options","volume":"17","author":"Serban","year":"2016","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0380","doi-asserted-by":"crossref","first-page":"9902","DOI":"10.1038\/srep09902","article-title":"A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations","volume":"5","author":"Serban","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0385","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0390","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jacl.2010.08.026","article-title":"The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review","volume":"4","author":"Simpson","year":"2010","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0395","first-page":"471","article-title":"Patterns of relationships between cardiovascular disease risk factors and neurocognitive function in African Americans","volume":"18","author":"Sims","year":"2008","journal-title":"Ethnicity & Disease"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0400","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1212\/WNL.0b013e3182661f63","article-title":"Obesity phenotypes in midlife and cognition in early old age: The Whitehall II cohort study","volume":"79","author":"Singh-Manoux","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0405","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2005.06.015","article-title":"Circulating biomarkers of cognitive decline and dementia","volume":"364","author":"Solfrizzi","year":"2006","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0410","first-page":"324","article-title":"HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier","volume":"6","author":"Sparks","year":"2002","journal-title":"The Journal of Nutrition, Health & Aging"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0415","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0420","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0425","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jamainternmed.2015.2092","article-title":"Statin therapy and risk of acute memory impairment","volume":"175","author":"Strom","year":"2015","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0430","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","article-title":"PCSK9 inhibitors and neurocognitive adverse events: Exploring the FDA directive and a proposal for N-of-1 trials","volume":"38","author":"Swiger","year":"2015","journal-title":"Drug Safety"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0435","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","article-title":"Statins and cognition: A systematic review and meta-analysis of short- and long-term cognitive effects","volume":"88","author":"Swiger","year":"2013","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0440","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/01.wnl.0000279333.77404.d7","article-title":"Association of statin use with cognitive decline in elderly African Americans","volume":"69","author":"Szwast","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0445","author":"US Food and Drug Administration"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0450","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/jnnp.2009.182519","article-title":"Cognitive decline precedes late-life longitudinal changes in vascular risk factors","volume":"81","author":"van Vliet","year":"2010","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0455","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","article-title":"Statin-associated memory loss: Analysis of 60 case reports and review of the literature","volume":"23","author":"Wagstaff","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0460","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamainternmed.2013.13656","article-title":"Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: A randomized clinical trial","volume":"174","author":"Williamson","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0465","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","article-title":"Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors","volume":"57","author":"Wolozin","year":"2000","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0470","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12035-014-8647-3","article-title":"Statins and neuroprotection: Basic pharmacology needed","volume":"50","author":"Wood","year":"2014","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0475","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2014.09.017","article-title":"Serum coenzyme Q10 and risk of disabling dementia: The Circulatory Risk in Communities Study (CIRCS)","volume":"237","author":"Yamagishi","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0480","article-title":"The impact of cerebrovascular aging on vascular cognitive impairment and dementia","author":"Yang","year":"2016","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0485","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/HJH.0000000000000253","article-title":"Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: A review of available trial evidence","volume":"32","author":"Zanchetti","year":"2014","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2016.11.001_bb0490","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1533317513517042","article-title":"Vascular risk factors and mild cognitive impairment in the elderly population in Southwest China","volume":"29","author":"Zou","year":"2014","journal-title":"American Journal of Alzheimer's Disease and Other Dementias"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816302108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816302108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T17:34:23Z","timestamp":1568568863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816302108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":98,"alternative-id":["S0163725816302108"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.001","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensive LDL-cholesterol lowering therapy and neurocognitive function","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}